MAPT and Alzheimer disease: Thus, as we have now observed in two assays designed to amplify AD tau filaments (here and [21]), an elevated baseline level of tau seeding activity in control brain specimens may be readily detectable due to similarities of AD and PART tau deposits and the frequent presence of the latter in the brains of clinically-normal individuals at quantities that may not be detectable by immunohistochemistry.